Skip to main content
. 2017 Mar 24;8(24):39001–39011. doi: 10.18632/oncotarget.16545

Figure 5. Co-expression of AFAP1-AS1 and PD-1 predicts the poorest outcomes.

Figure 5

Patients with high expression of both AFAP1-AS1 and PD-1 had a significantly less favorable prognosis than those with low expression of AFAP1-AS1 and/or PD-1.